IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Published: Dec 11, 2012
NEW YORK, Dec. 10, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Dr. Harry Fisch has joined the Board of Scientific Advisors and will head up the new Urology Department at IntelliCell.
IntelliCell's Chairman and CEO, Dr. Steven Victor stated, "Our Company is very pleased to announce today that Dr. Fisch is joining our Advisory Board and will be the Director of Urology for IntelliCell. He is a pioneering surgeon and respected on the national stage for his work on microsurgical techniques. I am looking forward to working with him as we expand the potential benefits of Regenerative Medicine into the practice of urology."
Said Dr. Fisch, "I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine. This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell's and improving the clinical outcomes of my patients."
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center.
About Dr. Fisch
Dr. Harry Fisch is Clinical Professor of Urology and Reproductive Medicine at Weill-Cornell Medical College/New York Presbyterian Hospital, and is a board-certified urologist and microsurgeon who is also one of the nation's leaders in the diagnosis and treatment of Men's health issues as well as sexuality and fertility problems in couples. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and repair of varicoceles. He has been frequently cited in a variety of publications, including USA Today, The New York Times, and The Washington Post and has appeared on television's 60 Minutes, 20/20, CNN and Today, among many others. He has been named to the "Best Doctors in America" and "New York Magazine Top Doctor" for the past 9 years.
Dr. Fisch has written two engaging and critically acclaimed books on the subject of male reproduction and sexuality.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Robert J. Sexauer
SOURCE IntelliCell BioSciences, Inc.